Result of AGM

RNS Number : 8845G

Redx Pharma plc

06 March 2018

 

REDX PHARMA PLC

("Redx" or "the Company")

Result of Annual General Meeting

Alderley Park, March 6 2018 - Redx (AIM: REDX), the drug discovery and development company, announces that all resolutions at the Group's Annual General Meeting, held today, were duly passed. 

For further information, please contact:

Redx Pharma Plc	T: [phone]
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated Advisor & Broker)	T: [phone]
Phil Davies
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting	T: [phone]
Simon Conway/Stephanie Cuthbert

About Redx Pharma Plc 

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.

 

END

 

 

RAGUGUBAWUPRGAQ